Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Entasis Therapeutics Holdings Inc. (ETTX)

6.16   0.5 (8.83%) 10-21 16:00
Open: 5.69 Pre. Close: 5.66
High: 6.16 Low: 5.69
Volume: 6,100 Market Cap: 81M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.166 - 6.196 6.196 - 6.221
Low: 5.622 - 5.655 5.655 - 5.683
Close: 6.108 - 6.162 6.162 - 6.208

Technical analysis

as of: 2019-10-21 4:36:03 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 7.92     One year: 9.25
Support: Support1: 5.70    Support2: 5.03
Resistance: Resistance1: 6.78    Resistance2: 7.92
Pivot: 5.78
Moving Average: MA(5): 5.84     MA(20): 5.87
MA(100): 6.46     MA(250): 6.27
MACD: MACD(12,26): -0.14     Signal(9): -0.20
Stochastic oscillator: %K(14,3): 58.61     %D(3): 43.58
RSI: RSI(14): 53.32
52-week: High: 9.25  Low: 3.97  Change(%): -15.8
Average Vol(K): 3-Month: 1971  10-Days: 1008

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
ETTX has closed above the upper band by 10.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to ETTX's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Entasis Therapeutics CEO: 'Our Antibiotics Work Differently'
Benzinga spoke with Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) CEO Manos Perros, Ph.D. for the latest news and updates in the company's pathogen-targeted antimicrobial pipeline. Benzinga: In late June, Entasis announced that David Meek was appointed as chairman of the board. With over 25 years' experience, and as the current CEO of Ipsen, what does the addition of Meek mean for the company? Perros: David brings extensive industry experience to our board and a strong commercial background across several therapeutic areas, but in particular in oncology and rare diseases, providing a valuable strategic perspective as we work to successfully develop and commercialize our innovative pathogen-targeted treatments. Meek is also the CEO of a multinational company and has deep experience in dealmaking. Interestingly, Meek’s specialty is not in infectious diseases; however, our antibiotics work differently from the way that typical antibiotics have been prescribed and commercialized in the past, so we are closer to a rare disease model.

Entasis Therapeutics reports Q1 results
No summary available.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  NA
Industry:  NA
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

Book Value (p.s.)
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E Growth Ratio
P/S 4229350.00

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.